Aberrant expression of homeobox genes has been described in primary leukemia blasts. We recently cloned a new cDNA, BP1, which is a member of the homeobox gene family. 
Introduction
We have cloned a novel cDNA which is a member of the Distal-less (DLX) family of homeobox (HB) genes. This cDNA, called BP1, encodes a repressor of two silencers of the human ␤-globin gene (GenBank Accession No. AF254115). 1 HB genes are characterized by a conserved 180 bp DNA sequence (the homeobox) encoding a DNA binding domain. 2 The largest family of HB genes, consisting of 39 members in humans, is called HOX. Recent studies have demonstrated that HB genes are expressed during hematopoiesis, where at least one of them has a role in differentiation. 3, 4 Altered expression of HB genes has been implicated in acute leukemias (reviewed in Look 5 ). In pre-B cell acute lymphocytic leukemias (ALL), for example, the HB gene Pbx1 is fused to E2A 6 and, in acute myeloid leukemia (AML), HOXA9 or PMX1 (another HB gene) is fused to NUP98. 7, 8 In other cases of leukemia not involving obvious cytogenetic changes, a HOX gene which is normally silent is either activated or perhaps not down-regulated in an early hematopoietic progenitor. 9 Ectopic expression of several HOX genes has been shown to be leukemogenic in mice, directly implicating this class of genes in leukemia. 3, 4, 10, 11 The aim of this study was to discover whether BP1 is activated in acute leukemias. In addition to BP1, analyses of two other cDNAs are included in these experiments, DLX7 and DLX4.
12-14 BP1, DLX7 and DLX4 appear to represent isoforms (alternative splice variants) of a common gene. Evidence for this includes our observations that the three homeoboxes are identical and the cDNAs share sequence identity in other regions. In addition, BP1 maps to chromosome 17q21, 15 the site of both DLX7 and DLX4. 12, 13 The transcriptional targets of DLX7 and DLX4 are unknown.
BP1 expression was measured in leukemia cell lines and in AML and ALL. AML is the most frequent adult leukemia and the second most frequent pediatric leukemia. 16, 17 Survival is poor in AML, with only 10-35% survival in adults and 30-40% survival in children. On the other hand, ALL is the most frequent leukemia in children, but is less common in adults. 18 Although aberrant expression of several molecular markers has been associated with AML and ALL, [3] [4] [5] 17, 19 there is clearly a need to identify additional markers which could aid in diagnosis, detection of residual disease and/or determination of appropriate therapy, as well as potentially serve as therapeutic targets.
Previously, we found that BP1 was highly expressed in erythroid and monocytic cell leukemia lines, with weak expression in megakaryocytic and monocytic/granulocytic leukemia cell lines. 1 Here, we extended that analysis to show that BP1 RNA was present in nine of the 14 lymphoid leukemia cell lines examined. However, BP1 expression was very low or undetectable in normal bone marrow, T lymphocytes or B lymphocytes, suggesting aberrant BP1 expression might be occurring in the BP1-positive cell lines.
Analysis of BP1 in both adult and pediatric AML was performed, revealing that BP1 is present in an average of 63% of cases, with more frequent expression in pediatric than adult AML. Expression of two other transcription factors was also assessed in each AML bone marrow sample, GATA-1 and cmyb, which are markers of early progenitors. [20] [21] [22] [23] [24] To compare the expression of BP1 in myeloid and lymphoid leukemias, expression analysis was performed in pediatric T cell ALL and in pediatric pre-B ALL. Interestingly, although BP1 RNA was found in 32% of T-ALL cases, it was not detectable in patients with pre-B ALL. To look at the distribution of BP1 in normal bone marrow, we analyzed expression in CD34 + and CD34 − progenitor cells. BP1 mRNA is enriched in CD34 − cells and barely detectable in CD34 + cells. The clonogenicity of BP1 was measured by testing the ability of K562 cells ectopically expressing cloned BP1 cDNA to grow in soft agar. The number of colonies was found to be significantly increased in the overexpressing clones compared with controls, indicating high level BP1 expression confers an increased oncogenic potential.
Materials and methods

Culture of leukemic cell lines
T and B-ALL cell lines were grown in RPMI 1640 (Gibco-BRL, Gaithersburg, MD, USA) supplemented with 2 mM glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate and 10% fetal bovine serum. Erythromyeloid cell lines were cultured in RPMI 1640 supplemented with 2 mM glutamine, 100 U/ml penicillin and 100 g/ml streptomycin, 10 mM Hepes and 10% fetal bovine serum.
Clinical samples
Normal bone marrows (BM) were obtained from the Brain Tissue Bank for Developmental Disorders at the University of Maryland. Adult AML bone marrow samples were obtained from the University of Maryland Greenebaum Cancer Center and The Johns Hopkins Cancer Center Cytogenetics Core Laboratory. Bone marrow samples from pediatric T and B-ALL patients were obtained from the Pediatric Oncology Group (POG). Informed consent was obtained from each patient or guardian at their local institutions. Leukemia samples contained at least 85% blasts. T and B lymphocytes from peripheral blood of normal donors were obtained by countercurrent elutriation followed by lineage specific separation using magnetic beads (Miltenyi Biotec, Auburn, CA, USA).
RT-PCR
Mononuclear cells were isolated for RNA analysis by FicollPaque. Total RNA was extracted from all samples using TRIzol Reagent (Gibco-BRL, Gaithersburg, MD, USA). For the reverse transcription (RT) reaction, 1 g of DNase I-treated RNA was added to 2.5 M oligo-d(T) primers (PE Biosystems, Foster City, CA, USA), 10 U RNase inhibitor (Gibco-BRL), 0.5 mM dNTPs, and 100 U MMLV-reverse transcriptase (Promega, Madison, WI, USA). The RT reaction was performed in a thermal cycler at 25°C for 10 min, 4 min ramp, 42°C for 50 min, and 99°C for 5 min. One to 2 l of this reaction was used in the PCR reaction. Primers specific for BP1, DLX4 and DLX7 were designed, and the PCR products were verified by restriction enzyme analysis. Linearity assays for each primer set have been performed and cycling conditions adjusted accordingly (data not shown). Primer sequences and PCR cycling conditions are shown in Table 1 .
Semi-quantitative RT-PCR
An oligonucleotide specific for each product was end-labelled with ␥-32 P-dATP and added to 10% of the PCR product (2.5 l). Hybridization was in the thermal cycler (94°C for 15 s; 42°C for 1 min). The hybridized product was electrophoresed on a 5% polyacrylamide gel, the gel was dried, and then exposed to film. The autoradiograph was aligned with the gel and bands were excised and quantitated by scintillation counting.
Expression was scored as negative (−), positive (+) or ambiguous (+/−) by normalizing against ␤-actin: a ratio was calculated by dividing the c.p.m. in the band representing BP1, DLX7 or DLX4 by the c.p.m. in the ␤-actin band from the same sample. One normal BM and one remission BM were included in each AML experiment; their ratios (6 repeats of each) averaged 0.01 for BP1, DLX7 and DLX4, and were the guide against which we scored a sample as −(0.0-0.10), +/−(0.11-0.15), +(Ͼ0.15) or ++(Ͼ0.45). Two phytohemagglutinin (PHA)-stimulated normal T cell cultures were the control for T cell ALL; their average ratios (10 repeats) were 0.05; the same criteria were used for scoring BP1, DLX7 and DLX4 as above. c-myb and GATA-1 are expressed in normal BM (our observations and Refs 20, 21). The average ratios in BM for c-myb and GATA-1 were 0.57 and 2.1, respectively. Samples with a ratio between 0.10 and 1.14 (c-myb) or 0.10 and 4.2 (GATA-1) were scored as (+), ie within the range of normal BM, and ratios greater than 1.14 (c-myb) or 4.2 (GATA-1) were scored as (++). Each RT-PCR and hybridization was performed twice, independently.
Isolation of CD34 cells
Bone marrow cells were aspirated from the posterior iliac crest of consenting healthy adult donors following guidelines approved by the Institutional Review Board for NIH. Cells were first prepared with Histopaque-1077 density gradient centrifugation. Mononuclear cells were then incubated with CD34 (QBEnd10)-conjugated magnetic microbeads (AmCellCorp, Sunnyvale, CA, USA) and processed through a MACS magnetic separation column (Miltenyi Biotec, Bergisch Gladbach, Germany) to obtain purified CD34 + cells. For higher purity of CD34 + cells, a second column run was used.
Purity of isolated CD34
+ cells was generally greater than 90%, and cell viability as evaluated by propidium iodide exclusion was always higher than 95%. Purity of the remaining CD34 − cells was greater than 95%.
Construction of cell lines overexpressing BP1
A BP1 cDNA fragment of 1013 bp containing the complete open reading frame was amplified by RT-PCR from K562 cell RNA using primers designed from the original cDNA. This fragment was cloned into pGEM7, sequenced, then subcloned into pRC/RSV (Invitrogen, Carlsbad, CA, USA) using HindIII and XbaI.
Statistical analysis
The significance of correlation between expression of BP1, DLX4, and DLX7 was assessed by Fisher's exact test. All P values reported were two-sided.
Results
Expression of BP1 in normal cells
RNA levels for BP1 were determined in four normal bone marrow samples and one bone marrow from an AML patient in remission, and in five PHA-stimulated T cell and five B cell preparations from normal bone marrow. Results obtained after semi-quantitative RT-PCR analysis of six representative samples are shown in Figure 1 . BP1 RNA was barely visible in any of these control samples; results were similar for DLX4 and DLX7. After a longer exposure of the autoradiograph, a faint band was seen in all six samples for several of the isoforms (data not shown).
Expression of BP1 in cell lines
Expression of BP1 was examined by RT-PCR in a number of leukemia cell lines. Fourteen cell lines of lymphoid origin were analyzed for BP1 expression. BP1 RNA was present in four of eight T cell ALL cell lines and in three of four lym- (Table 2 ). DLX7 and DLX4 RNA levels were also determined in the T cell ALL cell lines (Figure 2) , with co-expression of the three isoforms in the same cell lines. BP1 mRNA was also readily detectable in four of six erythromyeloid cell lines (K562, HEL, THP-1 and U937), with less expression in MEG-01 and HL60 cells. 1 Analysis of DLX7 and DLX4 in those cell lines showed that BP1, DLX7 and DLX4 were frequently co-expressed, with greatest expression of all three in K562 and U937 cells (data not shown). The observation that there was little or no expression of any of the isoforms in normal bone marrow (described above), compared with the expression found in diverse myeloid and lymphoid leukemia cell lines, led us to examine the relative expression of BP1, DLX7 and DLX4 in the bone marrow of acute leukemia patients using semi-quantitative RT-PCR.
Expression of BP1 in acute myeloid leukemias
Expression of BP1 was examined in both pediatric and adult AML patients. A total of 39 AML patients were studied, of whom 18 were under the age of 18 (pediatric; cases 8-27) and 21 were 18 years of age or older (adult; cases 29-49). Table 3 summarizes the analysis of the AML samples and the clinical data available for each patient, including cytogenetics, expression of surface markers and initial response to treatment; outcome data were not available for all patients and thus were excluded. Data are grouped according to the French-American-British (FAB) criteria. 30 Assignment of expression levels was made as described in Materials and methods. For this analysis, normal bone marrow was used as a negative baseline against which the clinical samples were compared. Samples classified as +/− were excluded from statistical analysis.
BP1 was overexpressed in a definitive manner in 81% (13/16) of the pediatric bone marrow samples and in 47% (9/19) of the adult cases. DLX7 was overexpressed in 59% (10/17) of pediatric and 38% (6/16) of adult cases, while DLX4 was overexpressed in 79% (11/14) of pediatric and 79% (15/19) of adult cases. An example of RT-PCR analysis show- 
Figure 2
Expression of BP1, DLX7 and DLX4 in T cell lineage lymphoid cell lines. Samples were analyzed using RT-PCR.
ing expression in selected samples is seen in Figure 3 . Here, patient 15 showed the greatest BP1 and DLX7 levels, with less DLX4 expression. The correlation between BP1 and DLX7 (P = 0.0002), BP1 and DLX4 (P = 0.0016), and DLX7 and DLX4 (P = 0.023) were statistically significant by Fisher's exact test.
Analysis of GATA-1 and c-myb, markers of primitive cells, was performed on the AML samples to indicate the differentiation state of cells expressing BP1. GATA-1 is believed to be involved in positive regulation of myeloid development and thought to be expressed in early progenitors, then downregulated in myeloid (but not erythroid) differentiation, making its expression in the myeloid pathway a sign of immaturity. 22 It is detected in acute leukemias characterized by expansion of early progenitors. 21 c-myb is expressed in immature hematopoietic cells, and its expression decreases as cells differentiate. 20, 23, 24 Since c-myb and GATA-1 are expressed in normal bone marrow (data not shown), 20 ,21 a classification of positive was given to samples expressing at the level of normal cells (see Materials and methods for details). We found that every AML sample exhibited c-myb expression at least equal to that in normal bone marrow, and 42% (13/31) exhibited greater expression. A higher proportion of pediatric than adult cases showed high-level c-myb expression, 59% in children compared with 21% in adults. GATA-1 was present in 77% (24/31) of AML cases, with 72% expression in children and 85% in adults.
Co-expression of DLX7 and DLX4 with BP1 was striking: 84% of BP1 + samples were DLX7 + and 100% were DLX4 + . GATA-1 was co-expressed in 74% of the samples, and all were c-myb positive, with 45% exhibiting high levels of cmyb. Another parameter in this study was analysis of surface markers. Interestingly, 64% of the BP1-positive samples were CD34 negative, while 73% were CD13 positive and 100% were CD33 positive.
Among the 39 AML patients, two had an abnormal chromosome 17q arm, the locus of BP1. 15 Patient 41, with acute promyelocytic leukemia, exhibited a t(15;17) translocation presumably involving the retinoic acid receptor on chromosome 17.
5 Patient 8 exhibited a t(11;17)(q23;q25) translocation. This translocation has been identified as fusing the MLL gene on chromosome 11q23 to either the AF17q25 gene or to MSF, both located on 17q25 and differing by a single base. [31] [32] [33] Since the MLL gene is known to activate several HOX genes, 34 it is tempting to speculate that the fusion protein may activate BP1 in this case.
Expression of BP1 in acute lymphoid leukemias
For comparison with the myeloid lineage leukemias, we examined 19 cases of pediatric T cell ALL (Table 4) . Here, 32% (6/19) were BP1 positive. Outcome data were not available for these patients. Analysis of DLX7 and DLX4 showed that 40% (6/15) of the cases were DLX7 positive, and 40% (6/15) were DLX4 positive. A comparison of expression of the three isoforms in AML and T cell ALL is seen in Figure 4 .
We next analyzed 19 pediatric patients with pre B-ALL. No detectable BP1 was observed in any of these cases, although the ␤-actin controls were normally expressed (data not shown).
BP1 expression in CD34
+ and CD34 − cells
To examine more precisely the reason for very low BP1 expression in normal bone marrow and to determine whether BP1 is expressed in early progenitors, BP1 expression was measured in CD34 + and CD34 − cells. There was clear expression in two independent isolates of CD34 − cells ( Figure  5, lanes 2 and 3) . In contrast, there was barely detectable BP1 mRNA in three independent samples of CD34 + bone marrow (lanes 4, 5 and 6). Expression in K562 cells is shown for comparison in lane 1, and ␤-actin was measured as a loading control.
Leukemia
Clonogenicity of K562 cells overexpressing BP1
Since the function of BP1 is not known in the context of leukemia, we tested the effect of enforced BP1 expression on the oncogenic potential of the erythroleukemia cell line K562. Four K562 cell lines stably overexpressing BP1 were constructed, as well as controls containing an empty vector (see Materials and methods). The BP1 mRNA levels in the stable Expression of BP1, DLX7 and DLX4 in acute myeloid leukemia. Samples from six patients are shown. (−) indicates expression equal to or less than normal controls; (+) indicates expression greater than controls; (+) indicates an expression ratio (defined in Materials and methods) at least three times greater than that for (+). Patients 8, 11, 15, and 19 are less than 18 years of age, while patients 27 and 34 are over 18 years old.
Table 4
Expression of BP1, DLX7 and DLX4 in children with T cell ALL Patient BP1 DLX7 DLX4
cell lines (8a, 8c, 8d and 8e) relative to the empty vector controls (7a and 7b) varied from five-to 21-fold, determined by RT-PCR (Table 5) . Stable cell lines were tested for their clonogenicity (ability to grow in soft agar), an indicator of oncogenic potential. Three of the four cell lines overexpressing BP1, 8a, 8c and 8d, exhibited significantly increased numbers of colonies able to grow in 0.5% soft agar per 15 000 cells plated compared with controls; there was a 45-fold increase in the number of colonies for 8c compared with 7a or 7b. These results indicate BP1 overexpression is associated with increased clonogenicity in K562 cells, predictive of an increase in oncogenicity.
Discussion
We have detected significant RNA expression of BP1, a new homeobox gene, in the bone marrow of 81% of pediatric AML patients, compared with 47% of adult patients. In contrast, expression of BP1 was not reproducibly found in normal bone marrow. The highest percentage of BP1 positives occurred in the FAB classification M5 (monocytic), in which 77% of AML cases were BP1 positive; bone marrow cells from 100% of the children in this category were BP1 positive. Two splice variants, DLX7 and DLX4, were co-expressed in 48% and 79% of AML patients, respectively. BP1, DLX7 and DLX4 levels were also assessed in 19 cases of pediatric T cell ALL. Although the frequency of expression was less in comparison with AML, BP1 was overexpressed in 32%, DLX7 in 50% and DLX4 in 40% of T cell ALLs, compared with weak or no expression in normal PHA-stimulated T lymphocytes. In sharp contrast, no BP1 expression was detected in pre-B ALL.
Although the reason for expression of BP1 in T cell ALL but not in pre B cell ALL is not obvious, this difference may provide a useful diagnostic distinction. c-myb was expressed in all AML samples, either at a level comparable to normal bone marrow or at a higher level. Expression of c-myb is associated with immaturity, 20, 23, 24 so those cases within the normal range may be arrested at an early progenitor stage. We speculate that higher c-myb expression may be part of the leukemogenic process since activation of c-myb causes leukemia in mice. 35 In this regard, of 11 samples which highly expressed c-myb and could be evaluated for BP1 expression, nine were BP1 positive.
There is a substantial body of data on expression of HOX genes in malignant hematopoietic cell lines. The HOX genes are clustered on four chromosomes, and the DLX genes are located in pairs on the same chromosomes. 3, 4, 12, 36 BP1 is situated at the 3Ј end of the HOXB cluster on chromosome 17.
15
HOXB genes are preferentially expressed in erythroid cells, including K562 and HEL cell lines. 3, [37] [38] [39] It is believed that genes in the HOX clusters are switched off or on in blocks in myeloid cells. 38, 40 Our data suggest that BP1 may be part of this coordinate regulation since its pattern of expression in erythromyeloid cell lines is similar to that of the adjacent HOXB genes. Transcripts of HOX genes have also been found in AML, T-ALL and pre B-ALL but, unlike BP1, they are readily detectable in normal bone marrow. 9, [41] [42] [43] [44] Notably, the expression of HOX genes is downregulated during normal hematopoietic differentiation but not in AML. 43 BP1 RNA expression in acute leukemias may represent a marker for the differentiation stage of the leukemic blasts and/or may be directly involved in leukemogenesis. Our data point to the possibility that BP1 expression in AML occurs in early progenitors: (1) As described above, all of the BP1-positive cells are also c-myb positive and 74% are GATA-1 positive, two indicators of early progenitors. 20, [22] [23] [24] ( 2) The barely detectable expression of BP1 seen in normal bone marrow is compatible with expression in primitive cells, which comprise a very small sub-population of normal bone marrow. (3) Over-
Figure 4
Comparison of expresssion of BP1, DLX7 and DLX4 in AML and T cell ALL. Black bars represent adult AML, gray bars pediatric AML, and white bars pediatric T cell ALL.
Figure 5
Expression of BP1 in CD34 + and CD34 − cells. Cells were sorted as described (Materials and methods), and BP1 mRNA was measured by RT-PCR. and lin − subpopulations, we do not know whether BP1 is expressed in stem cells. However, it is clear that BP1 is activated early in hematopoesis. We hypothesize that BP1 expression is then repressed during differentiation. This idea is strengthened by our observation that BP1 is down-regulated during erythroid differentiation of the cell line MB-02. 1 In support of a possible oncogenic role for BP1, we observed that stable cell lines overexpressing BP1 exhibited up to a 45-fold increase in clonogenicity. Moreover, its high frequency of expression in AML may indicate BP1 is an upstream factor in an oncogenic pathway. Further experiments are needed to delineate the roles of BP1 in normal hematopoiesis, to directly determine if it plays a role in neoplastic transformation, and to examine the clinical significance of its expression in acute leukemias.
